Possible risk factors for ovarian bleeding and hemoperitoneum were reported in just a few studies as a combination of the activated partial thromboplastin time and decreased factor XI and XII concentrations [42], prolongation of the activated partial thromboplastin time [19], intravenous diclofenac treatment before TVOR [41], mild factor VII deficiency and prolonged activated partial thromboplastin time [46], and violent coughing and movement of the body during TVOR [30]. This evidence concerns the gene F7 and hyperinsulinemic hypoglycemia, familial, 4.